Last reviewed · How we verify

NCT06363201

Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

Not yet recruiting NA Last updated 12 April 2024
What this trial tests

NA trial testing Ocoxin Oral solution in Advanced Cancer in 40 participants. Not yet recruiting.

Timeline
28 April 2024
Primary endpoint
15 December 2024
15 December 2025

Quick facts

Lead sponsorCatalysis SL
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment40
Start date28 April 2024
Primary completion15 December 2024
Estimated completion15 December 2025
Sites1 location across Honduras

Drugs / interventions tested

Conditions studied

Sponsor

Catalysis SL — full company profile →

Who can join

Adults 7 to 18, any sex, with Advanced Cancer or Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exploratory study to evaluate the effect and safety of the use of Ocoxin® oral solution on the quality of life of paediatric patients with advanced stage solid tumours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

Other Catalysis SL trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06363201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing